Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 1/20 | 0.61 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.61 |
| ▸ | MC4R | P32245 | 4/20 | 0.45 |
| ▸ | MC5R | P33032 | 4/20 | 0.45 |
| ▸ | MC3R | P41968 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7535687 | 0.94 | CCR6 (0.64) | CCR6PAX8MC4RMC5RMC3R | |
| SCHEMBL759516 | 0.93 | CCR6 (0.66) | CCR6PAX8MC4RMC5RMC3R | |
| SCHEMBL4890818 | 0.92 | CCR6 (0.59) | CCR6PAX8MC4RMC5RMC3R | |
| SCHEMBL5557184 | 0.91 | CCR6 (0.58) | CCR6PAX8ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL10232646 | 0.90 | CCR6 (0.57) | CCR6PAX8ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL19795748 | 0.89 | CCR6 (0.58) | CCR6PAX8MC5RALDH1A1MAPK1 | |
| SCHEMBL29875737 | 0.87 | CCR6 (0.56) | CCR6PAX8MC4RMC5RMC3R | |
| SCHEMBL15355992 | 0.86 | CCR6 (0.59) | CCR6PAX8ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL2076709 | 0.86 | CCR6 (0.59) | CCR6PAX8MC4RMC5RMC3R | |
| SCHEMBL17377997 | 0.86 | CCR6 (0.61) | CCR6PAX8MC4RMC5RMC3R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174459-A1 | LIPID CONTAINING FORMULATIONS | ARBUTUS BIOPHARMA CORPORATION (US) | 2023-06-08 | — | — | US | disclosed |
| US-20180065918-A1 | LIPID CONTAINING FORMULATIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-03-08 | — | — | US | disclosed |
| US-9663449-B2 | — | — | 2017-05-30 | — | — | US | disclosed |
| US-20140121393-A1 | LIPID CONTAINING FORMULATIONS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2014-05-01 | — | — | US | disclosed |
| US-8642076-B2 | Lipid containing formulations | TEKMIRA PHARMACEUTICALS CORPORATION | 2014-02-04 | — | — | US | disclosed |
| US-20120046478-A1 | LIPID CONTAINING FORMULATIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| US-8034376-B2 | Lipid containing formulations | Alnylam Pharamaceticals, Inc. (US) | 2011-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180065918-A1 | LIPID CONTAINING FORMULATIONS | LIPA, POLRMT, PHOSPHO1 | CCR6 2172/4885PAX8 3267/4885MC4R 2549/4885 |
| US-20230174459-A1 | LIPID CONTAINING FORMULATIONS | LIPA, POLRMT, PHOSPHO1 | CCR6 2172/4885PAX8 3267/4885MC4R 2549/4885 |
| US-20140121393-A1 | LIPID CONTAINING FORMULATIONS | LIPA, POLRMT, PHOSPHO1 | CCR6 2172/4885PAX8 3267/4885MC4R 2549/4885 |
| US-20120046478-A1 | LIPID CONTAINING FORMULATIONS | LIPA, POLRMT, PHOSPHO1 | CCR6 2172/4885PAX8 3267/4885MC4R 2549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.